181) clustering and gene ontology analysis, 23 molecular markers were significantly assoc |
182) tients with intermediate cytogenetics and molecular markers who may benefit from lom |
183) oduction and release of damage-associated molecular patterns (DAMPs) or Alarmins suc |
184) f factors-classified as damage-associated molecular patterns (DAMPs)-function as "fi |
185) genous and endogenous pathogen-associated molecular patterns (PAMPs) and damage-asso |
186) that are capable of recognizing divergent molecular patterns and catalysing synthesi |
187) lease of damage- and pathogen- associated molecular patterns from damaged tissue cau |
188) Damage-associated molecular patterns generated during ischem |
189) ost by recognition of pathogen-associated molecular patterns. |
190) While respiratory sensitization by high molecular weight (HMW) materials is recogn |
191) e differential biological effects of high molecular weight (HMW-HA) and low molecula |
192) Blends of low molecular weight (LMW) and high molecular |
193) ransdermal delivery of lipophilic or high molecular weight drugs. |
194) arized neutrophil morphology revealed the molecular weight of the active factors to |
195) pids are typically biocompatible and high molecular weight polymers are mechanically |
196) esmin isoprotein that migrates at a lower molecular weight range than wild type desm |
197) the genetic drivers of individual genetic/molecular subtypes. |
198) o unravel the complex relationships among molecular subtypes and effects exerted by |
199) trial cancer through to the four distinct molecular subtypes identified by The Cance |
200) We identify three major molecular subtypes of AD corresponding to |
201) lar functions they regulate across common molecular subtypes of breast cancer. |
202) 3FA will not exert uniform effects on all molecular subtypes of the disease. |
203) could lead to new therapeutic approaches/molecular targets that can mitigate the ri |
204) e encouraged scientists to identify novel molecular targets and develop alternative |
205) New molecular targets are continually being so |
206) at WDR26-CTLH and MTF2-PRC2 are promising molecular targets for new approaches to my |
207) he unknown etiology of AD and provide new molecular targets for use in therapeutic a |
208) t and hyperuricemia, but also suggest new molecular targets. |
209) However, the identity of additional molecular changes associated with MyD88 in |
210) Several studies investigated molecular changes in the different tumor t |
211) sue have identified distinct cellular and molecular changes in the diseased brain, s |
212) Understanding molecular changes underlying the developme |
213) , and real-time PCR were used to evaluate molecular changes. |
add keyword